Drug intelligence / Profile preview

von willebrand factor + factor viii

Development stage: Preclinical
Lead developer: Octapharma
Administration: Intravenous

Overview

A combination product containing von Willebrand factor (VWF) and coagulation factor VIII (FVIII) that is used to treat bleeding disorders. VWF acts as a carrier and stabilizing protein for factor VIII, which is prone to rapid proteolysis and clearance from plasma. This complex helps clot the blood when an injury occurs by promoting platelet adhesion to damaged vascular sub-endothelial matrix and platelet aggregation. It is primarily used to treat von Willebrand disease (VWD) and hemophilia A in patients who do not produce enough of these factors naturally.

Brand names: AlphanateHumate-PWilate
Other names: Antihemophilic factor VIII and von Willebrand factorFactor VIII / VWF complex

Targets

F8 (Coagulation Factor VIIIa)

Beyond the preview

Go deeper on von willebrand factor + factor viii.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on von willebrand factor + factor viii.

Explore the full profile